Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Stephenson KE, Le Gars M, Sadoff J, de Groot AM, Heerwegh D, Truyers C, Atyeo C, Loos C, Chandrashekar A, McMahan K, Tostanoski LH, Yu J, Gebre MS, Jacob-Dolan C, Li Z, Patel S, Peter L, Liu J, Borducchi EN, Nkolola JP, Souza M, Tan CS, Zash R, Julg B, Nathavitharana RR, Shapiro RL, Azim AA, Alonso CD, Jaegle K, Ansel JL, Kanjilal DG, Guiney CJ, Bradshaw C, Tyler A, Makoni T, Yanosick KE, Seaman MS, Lauffenburger DA, Alter G, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H, Barouch DH. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021 Mar 11:e213645. doi: 10.1001/jama.2021.3645. Epub ahead of print. PMID: 33704352; PMCID: PMC7953339.

A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine

Building Trust in COVID-19 Vaccines and Beyond Through Authentic Community Investment

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Sadoff, Jerald, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne M. De Groot, Jeroen Stoop, Sarah Tete, Wim VanDamme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan De Hoon, William Smith, Kathryn Stephenson, Stephen De Rosa, Kristen Cohen, Juliana McElrath, Emmanuel Cormier, Gert Scheper, Dan Barouch, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Johan Van Hoof, and Henneke Schuitemaker. “Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine.” The New England Journal of Medicine (2021). Print.

Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention

Stephenson KE, Wagh K, Korber B, Barouch DH. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. Annu Rev Immunol. 2020;38:673‐703. doi:10.1146/annurev-immunol-080219-023629

Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor

Dussupt V, Sankhala RS, Gromowski GD, et al. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nat Med. 2020;26(2):228‐235. doi:10.1038/s41591-019-0746-2

Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial

Stephenson KE, Wegmann F, Tomaka F, et al. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22) [published online ahead of print, 2020 Feb 17] [published correction appears in Lancet HIV. 2020 Feb 28;:]. Lancet HIV. 2020;S2352-3018(20)30001-1. doi:10.1016/S2352-3018(20)30001-1

HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH*, Korber B*. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 2019; 25:59-72.

Zika virus vaccines.

Abbink P, Stephenson KE, Barouch DH. Zika virus vaccines. Nat Rev Microbiol. 2018 Oct;16(10):594-600. doi: 10.1038/s41579-018-0039-7. Review. PubMed PMID: 29921914; PubMed Central PMCID: PMC6162149.

Therapeutic vaccination for HIV: hopes and challenges.

Stephenson KE. Therapeutic vaccination for HIV: hopes and challenges. Curr Opin HIV AIDS. 2018 Sep;13(5):408-415. doi: 10.1097/COH.0000000000000491. Review. PubMed PMID: 29957615.